Year-end is the time for employers to revisit their pharmacy strategy

As you head into open enrollment planning, 2027 budget discussions and strategic vendor evaluations, the final months of the year represent one of the most important times to review your organization’s pharmacy strategy. The cost of specialty drugs is rising. The number of people using specialty drugs is also rising. GLP-1 interest is still high. The market for cell and gene therapy is changing. These factors are making employers reconsider pharmacy decisions and look for more transparency, accountability and value. As the market continues to evolve, you should proactively review pharmacy solutions.

PBM request for proposal: A timely strategic discussion

The pharmacy benefit manager (PBM) marketplace is changing rapidly. There are new pricing models, regulatory pressures and increased employer scrutiny. Evaluating alternatives to your current PBM can uncover substantial savings. Many employers are increasingly looking to validate competitiveness, reduce pharmacy spending, strengthen contract terms and improve transparency. A PBM request for proposal can help you assess the market, identify savings opportunities and negotiate stronger contractual protections.

Cardiometabolic strategy remains a priority

Interest in obesity management, GLP-1 utilization and broader cardiometabolic health continues to accelerate. As you assess affordability, access and long-term sustainability, consider how your cardiometabolic strategy fits within broader benefit planning. Pharmacy strategy is now more closely linked to medical benefits, condition management programs, point solutions, benefits compliance and workforce health goals.

Cell and gene therapy: Preparing for what's next

Although usage is currently low, there's concern about the financial impact of emerging cell and gene therapies. Use predictive analytics to understand potential exposure by identifying members who may be eligible for newly approved or expected therapies.

Act before year-end

The coming months present a valuable opportunity to engage in forward-looking pharmacy discussions. Whether the conversation begins with PBM competitiveness, cardiometabolic strategy, GLP-1 management, cell and gene therapy preparedness or overall pharmacy cost trends, now’s the time to make informed decisions and prepare for 2027.